Spots Global Cancer Trial Database for lenalidomide
Every month we try and update this database with for lenalidomide cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma | NCT05575973 | Diffuse Large B... | Mitoxantrone Hy... Rituximab Lenalidomide | 60 Years - 75 Years | Huazhong University of Science and Technology | |
| PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma | NCT04040491 | Peripheral T-ce... | PD-1 blocking a... | 14 Years - 65 Years | Zhengzhou University | |
| Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma | NCT04091126 | Multiple Myelom... | Belantamab mafo... Bortezomib Lenalidomide Dexamethasone | 18 Years - | GlaxoSmithKline | |
| A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible | NCT05280275 | Multiple Myelom... Neoplasms Neoplasms, Plas... Gammopathy, Mon... Paraproteinemia... Blood Protein D... Haematologic Di... Corneal Disease | Belantamab Mafo... Daratumumab Lenalidomide Dexamethasone | 18 Years - | Hellenic Society of Hematology | |
| Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01886859 | Recurrent B-Cel... Recurrent Chron... Recurrent Small... Refractory B-Ce... Refractory Chro... Refractory Smal... | Ibrutinib Lenalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL | NCT04404283 | Diffuse Large B... | Brentuximab ved... Rituximab Lenalidomide Placebo | 18 Years - | Seagen Inc. | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma | NCT01348919 | Multiple Myelom... | CEP-18770 Lenalidomide Dexamethasone | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma | NCT00799513 | Diffuse Large B... | Lenalidomide | 18 Years - | IRCCS San Raffaele | |
| Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant | NCT02038153 | Acute Myeloid L... Adult Acute Mye... | Laboratory Biom... Lenalidomide | 60 Years - 80 Years | Albert Einstein College of Medicine | |
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | NCT05827016 | Multiple Myelom... | Iberdomide Lenalidomide | 18 Years - | Bristol-Myers Squibb | |
| Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic Leukemia | NCT00759603 | Chronic Lymphoc... Small Lymphocyt... | Lenalidomide Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis | NCT03252600 | Recurrent Prima... | Cyclophosphamid... Dexamethasone Elotuzumab Laboratory Biom... Lenalidomide Pharmacological... | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients | NCT05802992 | Multiple Myelom... | Colchicine Lenalidomide | 18 Years - 80 Years | Affiliated Hospital of Nantong University | |
| Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors | NCT01166035 | Solid Tumors | Lenalidomide Cetuximab | 18 Years - 80 Years | Medical University Innsbruck | |
| Safety And Efficacy Of Azacitidine, and Lenalidomide In Higher Risk Myelodysplastic Syndrome | NCT01053806 | Myelodysplastic... | 5-Azacytidine a... | 18 Years - | Tel-Aviv Sourasky Medical Center | |
| Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma | NCT01054144 | Multiple Myelom... | Lenalidomide Prednisone Dexamethasone | 65 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. | NCT00963534 | Mantle Cell Lym... | lenalidomide, b... lenalidomide, b... | 65 Years - | Lund University Hospital | |
| Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma | NCT05804032 | Multiple Myelom... | Isatuximab Isatuximab Lenalidomide Bortezomib Dexamethasone | 18 Years - 70 Years | University of Heidelberg Medical Center | |
| Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma | NCT03333746 | Recurrent Plasm... Refractory Plas... | Laboratory Biom... Lenalidomide Nivolumab Pharmacological... | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone | NCT03104842 | Multiple Myelom... | Isatuximab Carfilzomib Lenalidomide Dexamethasone | 18 Years - | Universitätsklinikum Hamburg-Eppendorf | |
| Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide | NCT01794039 | Recurrent Plasm... Refractory Plas... | Dexamethasone Lenalidomide Pomalidomide | 18 Years - | Mayo Clinic | |
| LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) | NCT04446962 | Lymphoma, Large... Central Nervous... | Lenalidomide Ibrutinib | 18 Years - 65 Years | Institut Curie | |
| Safety & Efficacy Study of Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma | NCT02875067 | Relapsed Hodgki... Relapsed Non-Ho... | Pembrolizumab Lenalidomide | 18 Years - | NYU Langone Health | |
| Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L | NCT00807599 | Multiple Myelom... | Stem cell trans... lenalidomide an... | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma | NCT05288062 | Plasma Cell Mye... Recurrent Plasm... Refractory Plas... Smoldering Plas... | Bone Marrow Bio... Dexamethasone Lenalidomide Pomalidomide | 18 Years - | Mayo Clinic | |
| Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma | NCT02492750 | Indolent Plasma... Plasma Cell Mye... Smoldering Plas... | Anakinra Dexamethasone Laboratory Biom... Lenalidomide Placebo | 18 Years - | Mayo Clinic | |
| Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia | NCT00843882 | Anemia Chronic Myelomo... de Novo Myelody... Myelodysplastic... | Bone Marrow Bio... Epoetin Alfa Laboratory Biom... Lenalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial | NCT00717756 | Liver Cancer | lenalidomide | 19 Years - | Brown University | |
| Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis | NCT00564889 | Multiple Myelom... | cyclophosphamid... dexamethasone lenalidomide | 18 Years - | Mayo Clinic | |
| Lenalidomide Plus Rituxan for Untreated Mantle Cell Lymphoma | NCT01472562 | Mantle Cell Lym... | lenalidomide rituximab | 18 Years - | Weill Medical College of Cornell University | |
| Lenalidomide Maintenance Therapy in Patients With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | NCT00720850 | Myelodysplastic... Acute Myelogeno... | lenalidomide | 18 Years - | Technische Universität Dresden | |
| Chlorambucil + Lenalidomide and Lenalidomide Maintenance in Untreated Elderly With Chronic Lymphocytic Leukemia (CLL) | NCT01403246 | Chronic Lymphoc... | Lenalidomide; C... | 60 Years - | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma | NCT05351593 | CNS Lymphoma Primary Central... Secondary Centr... | Tafasitamab Lenalidomide | 18 Years - | University of California, San Francisco | |
| A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma | NCT04722146 | Multiple Myelom... | Teclistamab Daratumumab Pomalidomide Lenalidomide Bortezomib Nirogacestat | 18 Years - | Janssen Research & Development, LLC | |
| A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | NCT01217957 | Multiple Myelom... | Ixazomib Lenalidomide Dexamethasone | 18 Years - | Takeda | |
| Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | NCT00114101 | DS Stage I Mult... DS Stage II Mul... DS Stage III Mu... Refractory Mult... Smoldering Mult... | Autologous Hema... Laboratory Biom... Lenalidomide Melphalan Peripheral Bloo... Placebo Adminis... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | NCT00553644 | Recurrent Mantl... | Bortezomib Laboratory Biom... Lenalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin's Lymphomas | NCT04435743 | Non-hodgkin Lym... | Lenalidomide | 18 Years - | Ruijin Hospital | |
| Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | NCT05861050 | Blastoid Varian... Mantle Cell Lym... Pleomorphic Var... | Biopsy Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Glofitamab Lenalidomide Obinutuzumab Positron Emissi... Venetoclax | 18 Years - 80 Years | City of Hope Medical Center | |
| Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL | NCT04134936 | Diffuse Large B... | Tafasitamab Tafasitamab plu... | 18 Years - | MorphoSys AG | |
| Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma | NCT02142049 | Diffuse Large B... Diffuse Large B... | Ibrutinib DA-EPOCH-R Lenalidomide | 18 Years - | Pharmacyclics LLC. | |
| MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL) | NCT04110301 | Follicular Lymp... | Recombinant Hum... Lenalidomide | 18 Years - | Beijing Mabworks Biotech Co., Ltd. | |
| Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma | NCT01054144 | Multiple Myelom... | Lenalidomide Prednisone Dexamethasone | 65 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Lenalidomide as Second-line Treatment for Advanced Hepatocellular Carcinoma | NCT01545804 | Liver Cancer | Lenalidomide | 20 Years - | National Taiwan University Hospital | |
| Lenalidomide and Obinutuzumab for Previously Untreated CLL | NCT02371590 | Chronic Lymphoc... | Lenalidomide Obinutuzumab | 18 Years - | University of California, San Diego | |
| Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer | NCT01373294 | Bladder Cancer | Bacille Calmett... Lenalidomide | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma) | NCT01938001 | Lymphoma, Non-H... | Rituximab Lenalidomide Placebo | 18 Years - | Celgene | |
| International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab | NCT05669989 | Plasma Cell Mye... | Isatuximab IV (... Cemiplimab (SAR... Dexamethasone Lenalidomide Pomalidomide Isatuximab SC (... | 18 Years - | Sanofi | |
| Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant | NCT03015792 | Recurrent Plasm... Refractory Plas... | Dexamethasone Ibrutinib Laboratory Biom... Lenalidomide Pharmacological... Quality-of-Life... | 18 Years - | Mayo Clinic | |
| First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade | NCT01215344 | Multiple Myelom... | VELCADE Lenalidomide Dexamethasone DVT prophylaxis Bisphosphonates Liposomal doxor... Dexamethasone | 18 Years - 70 Years | Vanderbilt-Ingram Cancer Center | |
| VitD3 Supplementation in Patients With Multiple Myeloma | NCT05846880 | Multiple Myelom... | Lenalidomide Vitamin D - Int... Vitamin D - The... | 18 Years - | Augusta University | |
| A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma | NCT01460940 | Adult Lymphocyt... Adult Lymphocyt... Adult Mixed Cel... Adult Nodular L... Adult Nodular S... Recurrent Adult... | panobinostat lenalidomide | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma | NCT00064038 | Multiple Myelom... Plasma Cell Neo... | dexamethasone lenalidomide placebo | 18 Years - | SWOG Cancer Research Network | |
| Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia | NCT01271283 | Chronic Lymphoc... Stage III Chron... Stage IV Chroni... | Diagnostic Labo... Lenalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone and MLN9708 After Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly-diagnosed Symptomatic Multiple Myeloma | NCT02406144 | Multiple Myelom... | MLN9708 Lenalidomide Dexamethasone | 18 Years - 67 Years | PETHEMA Foundation | |
| Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma | NCT01121757 | Follicular Lymp... Marginal Zone L... | azacitidine lenalidomide | 18 Years - | Duke University | |
| Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide | NCT03411031 | Multiple Myelom... | Elotuzumab Lenalidomide Dexamethasone | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma | NCT03019640 | Mantle Cell Lym... Recurrent Diffu... Recurrent Folli... Recurrent Indol... Refractory Diff... Refractory Foll... Refractory Indo... | Autologous Hema... Carmustine Cord Blood-deri... Cytarabine Etoposide Filgrastim Lenalidomide Melphalan Rituximab | 15 Years - 70 Years | M.D. Anderson Cancer Center | |
| A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) | NCT03173092 | Multiple Myelom... | Ixazomib Lenalidomide Dexamethasone | 18 Years - | Takeda | |
| Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type | NCT00923663 | MALT Lymphoma | Lenalidomide | 18 Years - 80 Years | Medical University of Vienna | |
| Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma | NCT00729118 | Multiple Myelom... Plasma Cell Neo... | lenalidomide vorinostat | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| A Nationwide Phase 2 Trial of Patients With Smoldering and Active Multiple Myeloma (MM) | NCT03815279 | Multiple Myelom... Smoldering Mult... | Carfilzomib Lenalidomide Dexamethasone | 18 Years - | Landspitali University Hospital | |
| A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) | NCT04196491 | Multiple Myelom... | bb2121 Fludarabine Cyclophosphamid... Lenalidomide | 18 Years - | Celgene | |
| A Study to Collect and Evaluate the Safety and Efficacy Information of Korean Multiple Myeloma Patients Treated With REVLIMID®, After Approval of Marketing Authorization for New Drug in Korea | NCT02556905 | Multiple Myelom... | REVLIMID® Dexamethasone | 18 Years - | Celgene | |
| Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant | NCT00833534 | Leukemia Lymphoma | rituximab lenalidomide | 18 Years - | Fred Hutchinson Cancer Center | |
| Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance | NCT01647165 | Multiple Myelom... | Bortezomib Lenalidomide Dexamethasone | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma | NCT02481934 | Multiple Myelom... | NKAE cells infu... Lenalidomide Bortezomib | 20 Years - 80 Years | Hospital Universitario 12 de Octubre | |
| Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma | NCT02697344 | Recurrent Plasm... | Dexamethasone Laboratory Biom... Lenalidomide Pharmacological... R-(-)-Gossypol ... | 18 Years - | Mayo Clinic | |
| Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP | NCT02983097 | Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Burkitt Lymphom... Aggressive Marg... | Rituximab Cisplatin Carboplatin Dexamethasone Cytarabine Lenalidomide PegFilgrastim peripheral stem... | 18 Years - 70 Years | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH | |
| Lenalidomide and R-CHOP in B-cell Lymphoma | NCT00901615 | Lymphoma, Large... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... | Lenalidomide an... | 18 Years - 70 Years | Lymphoma Study Association | |
| Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma | NCT00966693 | Recurrent Plasm... Refractory Plas... | Dexamethasone Lenalidomide Thalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial | NCT05497804 | ISS Stage III P... Plasma Cell Mye... | Bone Marrow Asp... Carfilzomib Computed Tomogr... Daratumumab Dexamethasone Lenalidomide Magnetic Resona... Positron Emissi... | 18 Years - 80 Years | Mayo Clinic | |
| Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant | NCT01264315 | Multiple Myelom... | Lenalidomide | 18 Years - 65 Years | Fondazione EMN Italy Onlus | |
| A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma | NCT00413036 | Lymphoma, Non-H... | lenalidomide | 18 Years - | Celgene | |
| Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma | NCT05260619 | Central Nervous... | lenalidomide | 19 Years - | Seoul National University Bundang Hospital | |
| Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | NCT05243797 | Multiple Myelom... | Teclistamab Lenalidomide | 18 Years - | Stichting European Myeloma Network | |
| Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma | NCT01042704 | Myeloma | Bendamustine Lenalidomide Dexamethasone Aspirin Prophylaxis Antibiotic Biweekly Follow... Cyclical Follow... Restaging Post-Treatment ... | 18 Years - | University of Pittsburgh | |
| Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma | NCT00602641 | Multiple Myelom... | Laboratory Biom... Lenalidomide Melphalan Prednisone Quality-of-Life... Thalidomide | 18 Years - | National Cancer Institute (NCI) | |
| A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes | NCT00910858 | Low- or Interme... | Lenalidomide Recombinant hum... | 18 Years - | Celgene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
